-
Overweight and obesity among Israeli adolescents and the risk for serious morbidity in early young adulthood: a nationwide retrospective cohort study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-15 Yair Zloof, Maya Nitecki, Maya Simchoni, Ofek Adar, Avishai M Tsur, Estela Derazne, Dorit Tzur, Jacob Rotschield, Maya Braun, Orit Pinhas-Hamiel, Naomi Fliss Isakov, Hadar Milloh-Raz, Dan Nemet, Dror Dicker, Avi Moyal, Oded Scheuerman, Zivan Beer, Marius Braun, Arnon Afek, Hertzel C Gerstein, Gilad Twig
BackgroundMorbidities related to obesity are usually associated with its severity and duration. Yet, the onset of serious morbidities in early adulthood among otherwise healthy adolescents with obesity is understudied. We aimed to investigate the association between adolescent BMI and serious morbidities before age 25 years. MethodsIn this nationwide, retrospective cohort study, we included Israeli
-
Associations of obesity with co-morbidities in early adult life Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-15 Thorkild I A Sørensen
No Abstract
-
Putting wellbeing at the core of diabetes care Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-14
No Abstract
-
Setmelanotide for the treatment of severe early-childhood genetic obesity Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-13 Christian L Roth
No Abstract
-
Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-13 Jesús Argente, Charles F Verge, Uzoma Okorie, Ilene Fennoy, Megan M Kelsey, Casey Cokkinias, Cecilia Scimia, Hak-Myung Lee, I Sadaf Farooqi
BackgroundSetmelanotide, a melanocortin-4 receptor (MC4R) agonist, has been shown to reduce hunger and weight in patients aged 6 years and older with proopiomelanocortin (POMC) deficiency (including biallelic variants in proprotein convertase subtilisin/kexin type 1 [PCSK1]), leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS). No approved therapies for patients younger than 6 years old
-
Hypothalamic obesity: from basic mechanisms to clinical perspectives Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-12 Jesús Argente, I Sadaf Farooqi, Julie A Chowen, Peter Kühnen, Miguel López, Eugenia Morselli, Hoong-Wei Gan, Helen A Spoudeas, Martin Wabitsch, Manuel Tena-Sempere
Despite the diverse nature of obesity, there is compelling genetic, clinical, and experimental evidence that endorses the important contribution of brain circuits to this condition. The hypothalamus contains major regulatory circuits for bodyweight homoeostasis, the deregulation of which can lead to obesity. Although functional perturbation of hypothalamic pathways could lie at the basis of common
-
Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-11 Dianna J Magliano, Lei Chen, Jedidiah I Morton, Agus Salim, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Martti Arffman, Helen M Colhoun, Kyoung Hwa Ha, Tomoaki Imamura, György Jermendy, Dae Jung Kim, Zoltán Kiss, Didac Mauricio, Stuart J McGurnaghan, Yuichi Nishioka, Sarah H Wild, Klas Winell, Jonathan E Shaw
BackgroundPopulation-based incidence data on young-adult-onset type 1 diabetes and type 2 diabetes are limited. We aimed to examine secular trends in the incidence of diagnosed type 1 diabetes and type 2 diabetes with an age of onset between 15 and 39 years. MethodsIn this multicountry aggregate data analysis, we assembled eight administrative datasets from high-income jurisdictions and countries (Australia
-
Global diabetes incidence trends in young adults Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-11 Lars C Stene
No Abstract
-
Disease modifying therapies in diabetes and endocrinology Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-08 Chantal Mathieu
No Abstract
-
Staging schema for early diagnosis of prediabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-11-07 Michael Bergman, Muhammad Abdul-Ghani, Juliana Chan, Maria Inês Schmidt, Joon Ha, Sang Soo Kim, Arthur S Sherman, Ram Jagannathan, Jaakko Tuomilehto
No Abstract
-
Diabetes subtypes and patient-reported outcomes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-24 Frank J Snoek
No Abstract
-
Depression symptoms, wellbeing, health-related quality of life, and diabetes-related distress in novel subtypes of recent-onset diabetes in Germany: a 5-year observational follow-up study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-24 Jana Sommer, Sandra Olivia Borgmann, Veronika Gontscharuk, Oana Patricia Zaharia, Haifa Maalmi, Christian Herder, Robert Wagner, Klaus Strassburger, Martin Schön, Volker Burkart, Julia Szendroedi, Andreas F H Pfeiffer, Stefan Bornstein, Matthias Blüher, Jochen Seissler, Andreas L Birkenfeld, Svenja Meyhöfer, Michael Roden, Andrea Icks, Robert Wagner
BackgroundThe subjective experiences of individuals living with diabetes is commonly assessed with patient-reported outcomes (PROs; eg, depression symptoms, wellbeing, health-related quality of life [HRQOL], and diabetes-related distress). Cluster analyses have identified novel diabetes subtypes differing in phenotypic and metabolic characteristics. We aimed to investigate associations between these
-
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92) Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-23 Beryl Lin, Ruth L Coleman, Fiona Bragg, Ernesto Maddaloni, Rury R Holman, Amanda I Adler
BackgroundYounger-onset type 2 diabetes is associated with accelerated complications. We assessed whether complications and mortality rates differed for younger age compared with older age at diagnosis over 30 years of follow-up. MethodsIn this study, we used data from the UKPDS, collected between 1977 and 2007, of participants aged 25–65 years with newly diagnosed type 2 diabetes with younger-onset
-
Young adult-onset type 2 diabetes heralds a poor prognosis Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-23 Soon H Song, Brian M Frier
No Abstract
-
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-16 Luis Masana, Alberto Zambon, Claus Peter Schmitt, Christina Taylan, Joenna Driemeyer, Hofit Cohen, Paola Sabrina Buonuomo, Abdullah Alashwal, Mohammed Al-Dubayee, Naji Kholaif, José Luis Diaz-Diaz, Faouzi Maatouk, Sergio Martinez-Hervas, Brian Mangal, Sandra Löwe, Tracy Cunningham
BackgroundHomozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder characterised by extremely high concentrations of LDL cholesterol, leading to early-onset atherosclerosis. Lomitapide is an orally administered microsomal triglyceride transfer protein (MTP) inhibitor that effectively lowers LDL cholesterol and is approved for adults with HoFH. We aimed to investigate the efficacy
-
Lomitapide for the treatment of homozygous familial hypercholesterolaemia in children Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-16 Liam R Brunham, Robert A Hegele
No Abstract
-
Declaration of Lisbon Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-16 Catarina Limbert, Jamie Wood, Sabine Hofer, Jannet Svensson, Fergus Cameron, Roque Cardona-Hernandez, Sylvia Lion, David M Maahs
No Abstract
-
Is it time to revisit the recommendations for initiation of menopausal hormone therapy? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-14 Sasha Taylor, Susan R Davis
Findings from the Women's Health Initiative studies led to menopausal hormone therapy (MHT) guidelines generally recommending the initiation of MHT be limited to women within 10 years of their menopause or before the age of 60 years. This recommendation has led to women who experience troublesome menopausal symptoms and who have not commenced MHT within these limits often being denied this type of
-
Continuous glucose sensor accuracy: beyond the headline metric Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-14 Nick Oliver, Monika Reddy, Lala Leelarathna
The promotion of continuous glucose monitoring (CGM) to standard of care for type 1 diabetes and insulin-treated type 2 diabetes reflects a robust and wide evidence base for the technology's effectiveness supported by real-world efficacy data. Multiple CGM devices are available worldwide and are marketed, in part, based on accuracy data. In this Viewpoint, we argue that accuracy metrics are no longer
-
Stem-cell therapy for diabetes: the hope continues Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-10 The Lancet Diabetes & Endocrinology
No Abstract
-
Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013–17 in 63 countries worldwide: a population-based study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-07 Mengmeng Li PhD, Luigino Dal Maso PhD, Margherita Pizzato PhD, Salvatore Vaccarella PhD
The incidence of thyroid cancer has been increasing in many countries, mainly due to overdiagnosis. Given these rapid changes, we aim to assess the specific features of the thyroid cancer diagnosis epidemic and provide estimates of overdiagnosis across countries spanning five continents and identify areas in which coping strategies are needed.
-
The growing global burden of thyroid cancer overdiagnosis Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-07 Cari M Kitahara
No Abstract
-
Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1 Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-04 Prof Richard M Bergenstal MD, Björg Ásbjörnsdóttir MD, Sara K Watt MD, Prof Ildiko Lingvay MD, Julia K Mader MD, Tomoyuki Nishida MSc, Julio Rosenstock MD
Continuous glucose monitoring (CGM) can provide a comprehensive assessment of glycaemic control. This exploratory analysis of the ONWARDS 1 trial assessed CGM-based metrics and CGM-derived hypoglycaemia duration in insulin-naive individuals with type 2 diabetes treated with subcutaneous once-weekly insulin icodec (icodec) versus once-daily insulin glargine U100 (glargine U100).
-
Ultra-long-acting insulin: a new chapter in diabetes therapy? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-04 Muhammad Ali Karamat, Srikanth Bellary, Anthony H Barnett
No Abstract
-
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-04 European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC), Amany Elshorbagy, Alexander R.M. Lyons, Antonio J. Vallejo-Vaz, Christophe A.T. Stevens, Kanika I. Dharmayat, Julia Brandts, Alberico L. Catapano, Tomas Freiberger, G. Kees Hovingh, Pedro Mata, Frederick J. Raal, Raul D. Santos, Handrean Soran, Gerald F. Watts, Marianne Abifadel, Carlos A. Aguilar-Salinas
Statins are the cornerstone treatment for patients with heterozygous familial hypercholesterolaemia but research suggests it could increase the risk of type 2 diabetes in the general population. A low prevalence of type 2 diabetes was reported in some familial hypercholesterolaemia cohorts, raising the question of whether these patients are protected against type 2 diabetes. Obesity is a well known
-
Type 2 diabetes in familial hypercholesterolaemia: another look at traditional risk factors Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-10-04 Marina Cuchel, Archna Bajaj
No Abstract
-
Dysglycaemia in cardiovascular disease: what's the best glycaemic risk predictor? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-23 Stefano Del Prato
-
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-23 Prof André Lacroix MD, Prof Isabelle Bourdeau MD, Fanny Chasseloup PhD, Prof Peter Kamenický PhD, Antoine-Guy Lopez MD, Estelle Louiset PhD, Prof Hervé Lefebvre PhD
Aberrant G-protein coupled receptor (GPCR) expression is highly prevalent in cortisol-secreting primary bilateral macronodular adrenal hyperplasia (PBMAH) and unilateral adenomas. The aberrant expression of diverse GPCRs and their ligands play an important role in the over-function of various endocrine tumours. Examples include aberrant expression of MC2R, 5-HT4R, AVPR1A, LHCGR, and GnRHR in primary
-
Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-23 Giulia Ferrannini PhD, Prof Jaakko Tuomilehto PhD, Prof Guy De Backer PhD, Prof Kornelia Kotseva PhD, Linda Mellbin PhD, Prof Oliver Schnell PhD, Prof David Wood PhD, Prof Dirk De Bacquer PhD, Prof Lars Rydén PhD
Glucose perturbations can be detected by fasting plasma glucose (FPG), HbA1c, and the oral glucose tolerance test (OGTT). The highest yield is provided by OGTT. HbA1c is considered more practical. We compare the diagnostic and predictive performance of these glycaemic indicators based on combined data from the EUROASPIRE IV (EAIV) and V (EAV) studies.
-
Osteopenia: a key target for fracture prevention Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-23 Prof Ian R Reid MD, Michael R McClung MD
Osteopenia was originally a qualitative term denoting bone that appeared to be less dense on radiographs. Since 1994, it has also had the quantitative meaning of a bone mineral density (BMD) T-score between –1·0 and –2·5. More than 60% of White women older than 64 years are osteopenic. Although fracture risk is often lower in osteopenic women than in those with osteoporosis, their greater number means
-
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50 Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-13
The EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 2024; 12: 39–50—The appendix of this Article has been corrected as of Sept 13, 2024.
-
The unhealthy politics of health Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-12 The Lancet Diabetes & Endocrinology
-
Muscle matters: the effects of medically induced weight loss on skeletal muscle Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-09 Carla M Prado, Stuart M Phillips, M Cristina Gonzalez, Steven B Heymsfield
-
Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-06 Mehdi Maanaoui, Rémi Lenain, Yohann Foucher, Fanny Buron, Gilles Blancho, Corinne Antoine, Sophie Caillard, Laurence Kessler, Moglie Le Quintrec, Orianne Villard, Dany Anglicheau, Matthias Büchler, Albane Brodin-Sartorius, Luc Frimat, Paolo Malvezzi, Sandrine Lablanche, Lionel Badet, Laure Esposito, Mikael Chetboun, Aghiles Hamroun, Florence Vachiery-Lahaye
BackgroundIslet transplantation has been associated with better metabolic control and quality of life than insulin treatment alone, but direct evidence of its effect on hard clinical endpoints is scarce. We aimed to assess the effect of islet transplantation on patient-graft survival in kidney transplant recipients with type 1 diabetes. MethodsIn this retrospective cohort study, we enrolled all patients
-
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-06 Claire Vale, Peter J Godolphin, David Fisher, Peter W Horby, Mikhail N Kosiborod, Judith S Hochman, Katie Webster, Julian P T Higgins, Andrew D Althouse, Otavio Berwanger, Remo H M Furtado, Samvel B Gasparyan, Richard Haynes, Gary G Koch, Martin Landray, Eric Leifer, John Marshall, Srinivas Murthy, Matthew D Neal, Natalie Staplin, Manu Shankar-Hari
BackgroundSodium–glucose co-transporter-2 (SGLT2) inhibitors have been proposed as a potential treatment for adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective effects. Published evidence from randomised control trials (RCTs) does not provide evidence of benefit. We aimed to estimate the effect of oral administration of SGLT2 inhibitors compared with
-
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-06 Mikhail N Kosiborod, Sheryl L Windsor, Orly Vardeny, Jeffrey S Berger, Harmony R Reynolds, Stavroula Boumakis, Andrew D Althouse, Scott D Solomon, Ankeet S Bhatt, Alexander Peikert, James F Luther, Eric S Leifer, Andrei L Kindzelski, Mary Cushman, Michelle Ng Gong, Lucy Z Kornblith, Pooja Khatri, Keri S Kim, Lisa Baumann Kreuziger, Ali Javaheri, P Balasubraman
BackgroundPatients hospitalised for COVID-19 are at risk for multiorgan failure and death. Sodium–glucose co-transporter-2 (SGLT2) inhibitors provide cardiovascular and kidney protection in patients with cardiometabolic conditions and could provide organ protection during COVID-19. We aimed to investigate whether SGLT2 inhibitors can reduce the need for organ support in patients hospitalised for COVID-19
-
Islet transplantation in kidney transplant recipients with type 1 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-06 Shareen Forbes, Thomas W H Kay
-
Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-06 André J Scheen
-
International Day of Charity: what does charity mean for diabetes? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-05 David Beran, Stéphane Besançon
-
Correction to Lancet Diabetes Endocrinol 2024; 12: 602–03 Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-03
Aune D. Meat consumption and type 2 diabetes. Lancet Diabetes Endocrinol 2024; 12: 602–03—In this Comment, reference 10 should have been cited in the final sentence. This correction has been made to the online version as of Sept 3, 2024.
-
Reducing sodium intake: step-by-step targets yield success Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-09-03 Talha Burki
-
Adiposity and metabolic health in Asian populations: an epidemiological study using dual-energy x-ray absorptiometry in Singapore Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-29 Theresia Mina, Wubin Xie, Dorrain Yanwen Low, Xiaoyan Wang, Benjamin Chih Chiang Lam, Nilanjana Sadhu, Hong Kiat Ng, Nur-Azizah Aziz, Terry Yoke Yin Tong, Swat Kim Kerk, Wee Lin Choo, Guo Liang Low, Halimah Ibrahim, Liming Lim, E Shyong Tai, Gervais Wansaicheong, Rinkoo Dalan, Yik Weng Yew, Paul Elliott, Elio Riboli, John Chambers
BackgroundType 2 diabetes, cardiovascular disease, and related cardiometabolic disturbances are increasing rapidly in the Asia-Pacific region. We investigated the contribution of excess adiposity, a key determinant of type 2 diabetes and cardiovascular risk, to unfavourable cardiometabolic profiles among Asian ethnic subgroups. MethodsThe Health for Life in Singapore (HELIOS) Study is a population-based
-
Why does visceral adiposity not explain higher type 2 diabetes prevalence in Asian Indians? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-29 Viswanathan Mohan, Ranjit Mohan Anjana
-
Transitioning to stage 3 type 1 diabetes: when to start insulin Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-26 Rachel E J Besser, Kurt J Griffin
-
Sociodemographic and health-related differences in non-diabetic hyperglycaemia and undiagnosed type 2 diabetes in England during 2013–19: a cross-sectional study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-21 Emma Campbell, Ellie Macey, Caitlin Kneebone-Hopkins, Chris Shine, Vahé Nafilyan, Nicholas Brown, Martin White, Ross Jones, Kamlesh Khunti, Katie Finning
-
Paediatric thyroid lesions: lessons from recent guidelines Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Esther Diana Rossi, Huiying Wang, Vivian Lee Weiss
-
Closed-loop systems: a bridge to cell therapy for type 1 diabetes? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Sufyan Hussain, Katarina Braune, Shareen Forbes, Peter A Senior
-
Food additive emulsifiers and risk of type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Xi Fu, Yiwen Yuan, Yiqun Deng, Yu Sun
-
Reasons to not rethink the label anti-obesity medication Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Richard Armitage
-
Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1·97 million adults with 100 000 incident cases from 31 cohorts in 20 countries Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Chunxiao Li PhD, Tom R P Bishop ME, Fumiaki Imamura PhD, Stephen J Sharp MSc, Matthew Pearce PhD, Soren Brage PhD, Prof Ken K Ong FRCPCH, Prof Habibul Ahsan MD, Prof Maira Bes-Rastrollo PhD, Prof Joline W J Beulens PhD, Nicole den Braver PhD, Prof Liisa Byberg PhD, Scheine Canhada PhD, Prof Zhengming Chen DPhil, Hsin-Fang Chung PhD, Adrian Cortés-Valencia PhD, Luc Djousse MD, Jean-Philippe Drouin-Chartier
Meat consumption could increase the risk of type 2 diabetes. However, evidence is largely based on studies of European and North American populations, with heterogeneous analysis strategies and a greater focus on red meat than on poultry. We aimed to investigate the associations of unprocessed red meat, processed meat, and poultry consumption with type 2 diabetes using data from worldwide cohorts and
-
A roadmap for integrating mental health and diabetes services Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Khalida Ismail, Marietta Stadler, Melissa Holloway, Jonathan Valabhji
-
Food additive emulsifiers and risk of type 2 diabetes – Authors' reply Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Bernard Srour, Clara Salame, Mathilde Touvier
-
Meat consumption and type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Dagfinn Aune
-
Food additive emulsifiers and risk of type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Jieling Chen, Suilian Zheng
-
Food additive emulsifiers and risk of type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Ying Cui
-
Risk of new-onset diabetes with high-intensity statin use Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 David M Diamond, Kevin E Kip
-
Association of age with gaps in diabetes-related care and hospitalisations from childhood to young adulthood in Quebec, Canada: a cohort study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Meranda Nakhla, Elham Rahme, Marc Simard, Véronique Boiteau, Kaberi Dasgupta
-
Increased prevalence of younger onset type 2 diabetes: why and what could be done? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-16 Naveed Sattar, Brian Kennon, Anna D White
-
Male hypogonadism: pathogenesis, diagnosis, and management Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-16 Nipun Lakshitha De Silva, Nikoleta Papanikolaou, Mathis Grossmann, Leen Antonio, Richard Quinton, Bradley David Anawalt, Channa N Jayasena
Organic male hypogonadism due to irreversible hypothalamic–pituitary–testicular (HPT) pathology is easily diagnosed and treated with testosterone-replacement therapy. However, controversy surrounds the global practice of prescribing testosterone to symptomatic men with low testosterone and non-gonadal factors reducing health status, such as obesity, type 2 diabetes, and ageing (ie, functional hypogonadism)
-
Diabetes-related complications: a toll too high Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-08 The Lancet Diabetes & Endocrinology